CoChat

One‐year outcome with antidepressant treatment of bipolar depression – is the glass half empty or half full?

Acta Psychiatrica Scandinavica, Calabrese, Joseph · 2005 · Acta Psychiatrica Scandinavica
Cited by 9

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

We as providers focus on what we are able to do for our patients, the extent to which we are able to help our patients recover from their serious mental illness. Our patients on the contrary, focus on what we are unable to do for them, the magnitude of their unmet clinical need. Whether or not the glass (the state of the art) is viewed, as being ‘half empty or half full’ very much depends on personal perspective. Consumers tend to focus on unmet need, whereas we as providers tend to focus on incremental improvement (frequently modest) as steps in the right direction. If the glass were ‘half full’, we would have a plethora of large acute and long-term therapeutic effect sizes. Unfortunately, the effect sizes of most of our clinical interventions for serious mental illness are modest in size. In point of fact, it is a rare drug development effort that leads to a new treatment for a serious mental illness that has a large effect size. Cohen (1) defines an effect size as improvement over placebo divided by pooled standard deviation, and notes that large effect sizes are at least 0.8. For example, an effect size of 1.0 would suggest that the treatment was twice as effective as placebo. At first glance this sounds like clinically impressive improvement. However, using the three acute antidepressant studies in bipolar depression as an example, a more detailed look at the data highlight how modest our effect sizes really are. For example, improvement in the total score on the Montgomery Depression Rating Scale over placebo (the delta) was as following in each of the three large-scale bipolar depression studies: 5.9, 6.5, 3.1, 6.6, 6.1, and 6.5, for lamotrigine 50 mg, lamotrigine 200 mg, olanzapine monotherapy, olanzapine plus fluoxetine, quetiapine 300 mg and quetiapine 600 mg daily respectively (2-4). Most often, this means patients with severe illness experience only moderate improvement during the first 2 months of treatment. With rare exception, the vast majority of our clinical interventions have only modest effect sizes. This observation has significant ramifications as clinical interventions that have large effects tend to be used as monotherapies, whereas treatments that possess only medium effect sizes tend to be used in combination with other treatments. With this in mind, it is not surprising to note that the majority of our patients receive multiple interventions or medications concurrently for their illnesses. Unfortunately, it is a rare patient with a serious mental illness who recovers completely on one medication. If the glass were ‘half full’, we would have definitions of a marked response that represented clear, compelling, and robust evidence of improvement. In mood disorders research, the definition of a ‘marked response’ is typically only described as being a 50% decrease in a baseline symptom severity scale. Worse yet, in schizophrenia research, the definition of a ‘marked response’ is even more modest, and described as being only a 30% decrease in a baseline symptom severity scale. However, in both instances, it is worth noting that routine outcome analyses of acute studies, more often than not, now include remission rate analyses, which are more patient (consumer)-friendly measures of true clinically relevant improvement. We must conclude that the glass is most often ‘half empty’, and that the state of the art in the treatment of serious mental illness is not that good. So why is this degree of scientific rigour so important? It is important for clinical investigators to recognize the magnitude of the unmet need in serious mental illness. It is particularly important for pharmaceutical companies to accurately characterize the magnitude of the clinical effect and the limitations of new medications. Such scientific candor drives insightful observations about where we need to go and what we need to do next. Unmet need should drive future drug development. There is emerging consensus that the greatest unmet need in the clinical management of bipolar disorder is the acute and long-term treatment of depressive symptoms. It is quite clear that patients with bipolar disorder live their lives ‘below baseline’, and that the majority of our new treatments, manage symptoms from ‘above baseline’. There are convincing data that suggest that the vast majority of time spent symptomatic for a patient with bipolar I disorder, and to a much greater extend, patients with bipolar II disorder, is spent in the depressed phase of the illness. For example, Judd et al. (5, 6) reported that the ratio of time spent depressed to manic/hypomanic is 3 : 1 in bipolar I and 39 : 1 in bipolar II disorder. Regarding the data published by Joffe et al. (7) in this issue, they should be congratulated for writing up data that targets an area of such great unmet need. These authors present an open, non-random case series of patients with bipolar disorder meeting inclusion criteria as specified in the manuscript. These Canadian dat

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-0447.2005.00534.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. Cohen J., 1988, Statistical power analysis for the behavioral sciences, 8
  2. 10.1001/archpsyc.59.6.530 · DOI · Paper page
  3. 10.1111/j.1600-0447.2005.00583.x · DOI · Paper page

Cited by

See all 9

Metadata

Authors
Scandinavica, A. P., & Calabrese, J.
Venue
Acta Psychiatrica Scandinavica
Publisher
Wiley
Published
2005-07
Volume
112
Issue
2
Pages
85-87
ISSN
  • 0001-690X (ISSN-L)
  • 1600-0447
OpenAlex
W2012372208
Cited by
9
References
5
FWCI
0.73
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.